Phathom Pharmaceuticals (PHAT) Total Current Liabilities (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Total Current Liabilities for 9 consecutive years, with $153.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Total Current Liabilities rose 67.47% year-over-year to $153.8 million; the TTM figure through Jun 2026 stood at $153.8 million (up 67.47% YoY), while the FY2025 annual figure was $132.0 million, up 54.03% from the prior year.
• Total Current Liabilities climbed to $153.8 million in Q2 2026 per PHAT's latest filing, from $125.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $153.8 million in Q2 2026 and bottomed at $11.4 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $60.6 million across 5 years, with a median of $45.2 million in 2024.
• Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 72.1% — and 2024, when it surged 200.9%.
• Phathom Pharmaceuticals' Total Current Liabilities stood at $26.2 million in 2022, then jumped by 47.81% to $38.8 million in 2023, then jumped by 121.06% to $85.7 million in 2024, then soared by 54.03% to $132.0 million in 2025, then grew by 16.46% to $153.8 million in 2026.
• Business Quant data shows PHAT's Total Current Liabilities at $153.8 million in Q2 2026, $125.0 million in Q1 2026, and $132.0 million in Q4 2025.